RxDoctor Payments Data

Stephen Franklin, MD

Ophthalmology · Powell, TNNPI 1669556262

Payments from drug & device makers

$845in general payments, 2019–2025

Across 35 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$218
  • Tarsus Pharmaceuticals, Inc.$167
  • Sun Pharmaceutical Industries Inc.$144
  • AbbVie$127
  • Novartis$50
  • Alcon$37
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$845 in reported general payments places this provider in the 35th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$237,083
Medicare patients
821
Services billed
2,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast22$38,049
RestasisCyclosporine24$24,718
XdemvyLotilaner11$21,155
LumiganBimatoprost34$14,939
CombiganBrimonidine Tartrate/Timolol17$5,261
Alphagan PBrimonidine Tartrate12$4,041
Brimonidine Tartrate21$3,526
Latanoprost261$2,802
Prednisolone Acetate80$2,491
Timolol Maleate68$1,756
Tobramycin-DexamethasoneTobramycin/Dexamethasone19$963
Travoprost13$893
Ofloxacin56$656
Doxycycline Hyclate56$529
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$127$48,95987 claims
Bausch & Lomb Americas Inc.Xiidra$19$38,04922 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$167$21,15511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Powell

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →